

## Safety Alert

July 2024

### Menquadfi

EDA performs label update to include the following:

#### Dosage and administration:

Administer MenQuadfi as a single 0.5 mL injection intramuscularly.

#### *Primary Vaccination*

Individuals 2 years of age and older receive a single dose.

#### *Booster Vaccination*

A single dose of MenQuadfi may be administered to individuals 13 years of age and older who are at continued risk for meningococcal disease if at least 3 years have elapsed since a prior dose of meningococcal (groups A, C, W, Y) conjugate vaccine.

#### *Vaccination Following Prior Dose of Meningococcal Polysaccharide Vaccine*

A single dose of MenQuadfi may be administered if at least 3 years have elapsed since a prior dose of meningococcal polysaccharide vaccine.

#### Background:

- MenQuadfi® is a vaccine indicated for active immunization for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. MenQuadfi is indicated for use in individuals 2 years of age and older.
- MenQuadfi does not prevent N. meningitidis serogroup B disease.

#### References:

US FDA:

<https://www.fda.gov/media/137306/download>